Elekta (EKTA B)

Nasdaq Stockholm | Radiotherapy medtech and oncology software
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.
Free
No email, no account, no signup.
Pulling latest news for Elekta…
Bull
Bear
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – $4.99 $1.25
Signal
HOLD
Sentiment
2/10
Risk
8/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis – $4.99 $1.25
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has deteriorated further after the CMD: investors are focusing on guidance/targets and uncertainty around growth/order momentum, reinforcing the negative tone already driven by weak Q4 order intake.
Exchange
Nasdaq Stockholm
Sector
Radiotherapy medtech and oncology software
Market Cap
$2.2B

10 days ago 18 Jun 2026

Market sentiment

Sentiment has deteriorated further after the CMD: investors are focusing on guidance/targets and uncertainty around growth/order momentum, reinforcing the negative tone already driven by weak Q4 order intake.

Why HOLD ?

Hold: margin/cash-flow improvements and the cost program are supportive, but weak order intake raises uncertainty around forward revenue; wait for evidence of order recovery (Q1/Q2) before adding.
  • Maintain the current position; avoid adding until order intake stabilises and the impact of stricter order acceptance is visible in upcoming quarters.

Recent News

  • On 17 June 2026 Elekta held a Capital Markets Day, presenting new mid-term financial targets and more detailed FY 2026/27 guidance. The market reaction was negative, with the share down roughly 5–7% on the day (and remaining weak after CMD).

Bull case

- **FDA clearance** for Elekta Evo can support near-term momentum. - Early impact from **cost savings** may start to show.
Unlock to read more →

Bear case

- Ongoing **FX and tariff headwinds** may pressure reported results.
Unlock to read more →

Catalysts

27 Aug 2026 — Q1 2026/27 report (first quarter with full savings run-rate)

Unlock 3 more catalysts →

Dilution Risk

Assessment: Low

Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.

Want to read the full analysis?

Order a fresh analysis of Elekta – ready in your inbox in 5–15 minutes.

  • Signal + risk + sentiment
  • Bull/Bear case + triggers
  • Catalysts with dates
  • Saved as a webpage in your account
  • Ready in 5–15 min (email when ready)

Full analysis at introductory pricing — 7-day money-back guarantee.

7-day money-back guarantee · No lock-in period · Secure payment via Stripe

Fact-based analysis Updated weekly No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.